Absorbable Hemostat Gelatin Sponge Market Size, Share, Growth, and Industry Analysis, By Type (Large Size,Medium Size,Small Size), By Application (Hospitals,Clinics,Others), Regional Insights and Forecast to 2035

Unique Information about the Absorbable Hemostat Gelatin Sponge Market

Global Absorbable Hemostat Gelatin Sponge market size is estimated at USD 4143.66 million in 2026, set to expand to USD 6960.91 million by 2035, growing at a CAGR of 6.0%.

The Absorbable Hemostat Gelatin Sponge Market represents a specialized segment of the surgical hemostasis industry used to control bleeding during surgical procedures. Gelatin-based hemostatic sponges are bioabsorbable materials capable of absorbing nearly 35–45 times their weight in blood, making them widely adopted in over 60% of surgical bleeding control procedures. These products typically dissolve in 4–6 weeks after implantation, eliminating the need for surgical removal. Globally, more than 320 million surgical procedures are performed annually, and approximately 48% of these procedures require hemostatic agents such as absorbable gelatin sponges. The Absorbable Hemostat Gelatin Sponge Market Size is influenced by growing surgical volumes, with orthopedic surgeries increasing by 22% between 2018 and 2024, creating sustained demand for surgical bleeding control materials.

The United States represents a significant portion of the Absorbable Hemostat Gelatin Sponge Market due to its advanced healthcare infrastructure and high surgical volume. The country records approximately 51 million inpatient surgical procedures annually, and about 62% of these procedures require topical hemostatic products. Hospitals in the U.S. account for nearly 73% of total absorbable hemostat gelatin sponge usage, followed by outpatient surgical centers with 18% usage share. In orthopedic surgeries alone, more than 7.2 million procedures are performed annually, while cardiovascular surgeries exceed 1.5 million cases per year, both requiring effective bleeding control products. Around 68% of surgeons in U.S. hospitals report routine use of gelatin-based hemostats, making the country a dominant contributor to the Absorbable Hemostat Gelatin Sponge Market Analysis and Industry Outlook.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: About 64% demand growth comes from rising surgeries, 58% trauma procedures, 46% orthopedic operations, and 39% minimally invasive surgeries requiring hemostatic materials.
• Major Market Restraint: Around 42% hospitals cite cost sensitivity, 37% prefer alternatives, 29% surgeons report absorption limits, and 24% facilities face supply disruptions.
• Emerging Trends: Nearly 52% manufacturers develop improved formulations, 47% adoption in minimally invasive surgeries, 41% preference for sterile sponges, and 35% hospitals adopt advanced hemostatic technologies.
• Regional Leadership: North America leads with 38% share, Europe holds 29%, Asia-Pacific represents 23%, while Middle East & Africa account for about 10%.
• Competitive Landscape: About 44% market share belongs to top manufacturers, 31% to mid-tier companies, 15% to regional firms, and 10% emerging biotech companies.
• Market Segmentation: Medium sponges hold 41% usage, large sponges 36%, small sponges 23%, while hospitals account for 67% demand.
• Recent Development: Nearly 49% manufacturers introduced sterile sponges, 38% improved absorption designs, 33% expanded surgical approvals, and 27% adopted automated production systems.

Absorbable Hemostat Gelatin Sponge Market Latest Trends

The Absorbable Hemostat Gelatin Sponge Market Trends indicate strong technological progress in surgical hemostatic materials. Gelatin sponges are widely utilized in neurosurgery, cardiovascular surgery, orthopedic surgery, and dental surgery, with over 72% of hospitals worldwide integrating absorbable hemostatic products into surgical protocols. These sponges can absorb up to 40–50 times their weight in fluids, allowing surgeons to control bleeding rapidly in surgical sites. One major trend in the Absorbable Hemostat Gelatin Sponge Industry Analysis is the shift toward sterile ready-to-use sponge packaging, which now accounts for approximately 56% of hospital procurement orders. Pre-sterilized sponge variants reduce operating room preparation time by 12–18 minutes per procedure, improving surgical efficiency.

Another significant trend involves the integration of gelatin sponges with thrombin-based additives, which enhance clot formation efficiency by 35–45% compared with standard gelatin-only products. In trauma surgeries, where rapid hemostasis is critical, the use of combination hemostatic materials has increased by 28% since 2021. In addition, minimally invasive surgical procedures are driving adoption of smaller gelatin sponge formats. Around 61% of laparoscopic procedures require compact hemostatic materials, contributing to growing demand for small and medium sponge variants. The Absorbable Hemostat Gelatin Sponge Market Forecast suggests further expansion in surgical specialties such as neurology, where over 1.2 million neurosurgical procedures are conducted globally each year.

Absorbable Hemostat Gelatin Sponge Market Dynamics

DRIVER

"Rising number of surgical procedures worldwide"

The increasing number of surgical procedures is the primary driver of the Absorbable Hemostat Gelatin Sponge Market Growth. Globally, healthcare systems perform more than 320 million surgeries annually, with approximately 48–52% of procedures requiring hemostatic agents to manage intraoperative bleeding. Orthopedic surgeries alone exceed 22 million procedures per year, while cardiovascular surgeries surpass 6 million annually, both requiring advanced bleeding control solutions. In trauma care, nearly 40% of emergency surgeries involve active bleeding, increasing reliance on absorbable gelatin sponges. Additionally, the rise in chronic diseases contributes to surgical demand, as 463 million adults globally live with diabetes, often requiring surgical intervention. With hospitals seeking efficient hemostatic solutions that dissolve within 4–6 weeks, gelatin sponge products continue to gain preference in operating rooms worldwide.

RESTRAINT

"Availability of alternative hemostatic technologies"

The Absorbable Hemostat Gelatin Sponge Market faces restraint from the growing availability of alternative hemostatic agents such as oxidized regenerated cellulose, fibrin sealants, and synthetic polymer hemostats. These alternatives account for approximately 34% of hospital hemostatic product procurement. Fibrin-based sealants demonstrate clotting times nearly 28% faster than traditional gelatin sponges, making them attractive in specialized surgeries. Additionally, oxidized cellulose products are used in nearly 26% of neurosurgical procedures, creating competitive pressure on gelatin sponge products. Another restraint is shelf-life sensitivity; gelatin-based sponges generally maintain product stability for 24–36 months, whereas synthetic hemostatic agents can remain stable for up to 60 months. These competing technologies continue to influence purchasing decisions among hospitals and surgical centers.

OPPORTUNITY

"Expansion of minimally invasive surgeries"

Minimally invasive surgical techniques are creating significant opportunities in the Absorbable Hemostat Gelatin Sponge Market Opportunities landscape. Laparoscopic procedures account for nearly 54% of abdominal surgeries globally, and robotic-assisted surgeries exceed 1.8 million procedures annually. These techniques require compact, flexible hemostatic materials capable of being inserted through small surgical ports. Small and medium gelatin sponge products have seen usage growth of 31% in laparoscopic surgeries since 2020. Additionally, ambulatory surgical centers have increased by 19% worldwide in the past 5 years, creating new demand for portable hemostatic solutions. Surgeons prefer absorbable gelatin sponges in minimally invasive operations because they eliminate the need for removal and reduce postoperative complications by approximately 14% compared with non-absorbable hemostatic materials.

CHALLENGE

"Sterilization and quality compliance requirements"

Strict sterilization standards represent a major challenge for manufacturers operating in the Absorbable Hemostat Gelatin Sponge Market. Medical-grade gelatin must meet strict biocompatibility standards, including compliance with ISO 10993 testing protocols. Manufacturing facilities must maintain contamination control levels below 10 colony-forming units per cubic meter, increasing production complexity. Additionally, regulatory approvals for surgical hemostats require extensive clinical validation, with testing periods lasting 18–36 months in many regions. Raw material sourcing is another challenge because gelatin used in medical products must achieve purity levels exceeding 99% protein content. Quality assurance costs represent nearly 22% of total production expenses in the hemostatic sponge manufacturing industry. These regulatory and quality requirements create operational challenges for manufacturers seeking to expand production capacity.

Segmentation Analysis

The Absorbable Hemostat Gelatin Sponge Market Segmentation includes product types such as large size, medium size, and small size gelatin sponges, along with applications including hospitals, clinics, and other healthcare facilities. Medium-sized sponges dominate usage with approximately 41% share, while large sponges represent 36% and small sponges account for 23%. Hospitals represent the largest application segment with nearly 67% usage, followed by clinics with 21%, and other healthcare settings including ambulatory surgical centers accounting for 12%.

Download FREE Sample to learn more about this report.

By Type

Large Size: Large size absorbable hemostat gelatin sponges are widely used in high-bleeding surgical procedures such as cardiovascular surgery, orthopedic surgery, and trauma surgery. These sponges typically measure 80 mm × 50 mm × 10 mm and can absorb nearly 40–45 times their weight in blood. Large sponges account for approximately 36% of the Absorbable Hemostat Gelatin Sponge Market Share due to their effectiveness in large surgical cavities. In orthopedic surgeries, which exceed 22 million procedures globally each year, large gelatin sponges are used in approximately 48% of cases. Cardiovascular procedures, numbering more than 6 million annually, rely on large sponge formats in nearly 35% of operations.

Medium Size: Medium size gelatin sponges dominate the Absorbable Hemostat Gelatin Sponge Market Size with approximately 41% usage share across surgical procedures. Typical dimensions range from 50 mm × 30 mm × 10 mm, making them versatile for multiple surgical specialties. These sponges are widely used in general surgery, dental surgery, and gynecological procedures. Dental surgeries alone exceed 15 million procedures annually worldwide, with gelatin sponges used in approximately 58% of tooth extraction cases to control bleeding. Medium size sponges also show strong adoption in laparoscopic surgeries, where 54% of abdominal operations are performed using minimally invasive techniques.

Small Size: Small size absorbable hemostat gelatin sponges account for approximately 23% of the Absorbable Hemostat Gelatin Sponge Market Share. These sponges are typically sized around 20 mm × 20 mm × 7 mm, making them ideal for delicate procedures such as neurosurgery, ophthalmic surgery, and dental procedures. Neurosurgical operations exceed 1.2 million procedures annually, and small gelatin sponges are used in nearly 44% of cranial surgeries to control microvascular bleeding. In ophthalmic surgeries, which surpass 28 million procedures per year globally, small sponges are used in approximately 31% of cases.

By Application

Hospitals: Hospitals represent the largest application segment in the Absorbable Hemostat Gelatin Sponge Market with approximately 67% usage share. Globally, there are more than 165,000 hospitals, performing over 320 million surgeries annually. Gelatin sponges are used in nearly 62% of hospital surgical procedures involving bleeding control. Orthopedic departments within hospitals account for about 28% of gelatin sponge consumption, followed by cardiovascular surgery departments with 19% usage share. Hospitals prefer absorbable gelatin sponges because they dissolve naturally within 4–6 weeks, eliminating the need for removal procedures and reducing postoperative complications by approximately 12%.

Clinics: Clinics account for nearly 21% of the Absorbable Hemostat Gelatin Sponge Market Share, particularly in dental clinics, dermatology clinics, and minor surgical centers. There are approximately 2.7 million dental clinics worldwide, performing over 15 million surgical tooth extractions annually. Gelatin sponges are used in around 58% of these dental procedures to stop bleeding and promote clot formation. Dermatology clinics also utilize gelatin sponges in nearly 27% of minor surgical procedures such as lesion removal. Clinics prefer smaller sponge variants because they are easier to apply and require minimal preparation.

Others: Other healthcare facilities, including ambulatory surgical centers and specialty surgical units, account for approximately 12% of the Absorbable Hemostat Gelatin Sponge Market Usage. There are more than 30,000 ambulatory surgical centers globally, performing approximately 60 million outpatient procedures annually. Gelatin sponges are used in around 34% of these procedures, particularly in minimally invasive surgeries. Specialty surgical centers prefer gelatin sponges because they provide rapid hemostasis within 2–4 minutes and reduce surgical bleeding complications by nearly 15%.

Regional Outlook

The Absorbable Hemostat Gelatin Sponge Market shows varied regional distribution, with North America holding about 38% market share, followed by Europe at nearly 29%, Asia-Pacific around 23%, and Middle East & Africa approximately 10%. More than 320 million surgeries occur globally each year, and nearly 48% of procedures require hemostatic agents, driving consistent demand for absorbable gelatin sponge products across hospitals and surgical centers worldwide.

Download FREE Sample to learn more about this report.

North America

North America holds approximately 38% share of the Absorbable Hemostat Gelatin Sponge Market, supported by a highly developed healthcare infrastructure and high surgical procedure volumes. The United States alone performs more than 51 million inpatient and outpatient surgeries annually, while Canada contributes around 3.2 million procedures each year. Across North America, nearly 65% of hospitals utilize absorbable gelatin sponges as part of standard surgical bleeding control protocols. The region contains more than 6,100 hospitals in the United States and approximately 1,200 hospitals in Canada, creating a significant base of medical facilities that regularly procure hemostatic materials.

Orthopedic procedures are a major demand driver in the region, exceeding 7.2 million surgeries annually, and gelatin-based hemostats are used in approximately 58% of these procedures to control bone bleeding.

Cardiovascular surgeries represent another key application, with more than 1.5 million heart-related operations performed every year, where gelatin sponges are used in nearly 43% of cases. In neurosurgical procedures, which exceed 800,000 operations annually across North America, surgeons utilize small absorbable gelatin sponges in around 37% of procedures to manage microvascular bleeding. Ambulatory surgical centers are also expanding rapidly in the region, with more than 11,000 outpatient surgical centers operating across the United States, performing approximately 23 million procedures annually. Around 34% of these outpatient procedures require hemostatic materials, supporting steady demand for absorbable gelatin sponge products in the North American surgical supply market.

Europe

Europe represents approximately 29% of the global Absorbable Hemostat Gelatin Sponge Market Share, supported by strong healthcare systems and a large number of surgical procedures performed annually. The region conducts more than 90 million surgeries each year, with Germany performing over 17 million surgical procedures annually, France conducting approximately 11 million, and the United Kingdom carrying out around 10 million surgeries per year. Italy and Spain together contribute nearly 14 million surgical procedures annually, further strengthening regional demand for surgical hemostatic materials. Hospitals across Europe report that nearly 61% of surgical procedures require topical hemostatic agents, including gelatin sponges, to manage bleeding during operations. Orthopedic surgeries represent a significant portion of this demand, with more than 5.5 million orthopedic procedures performed annually across the region. Gelatin-based hemostatic sponges are used in approximately 52% of orthopedic surgeries to manage bone and tissue bleeding effectively.

The European healthcare system includes more than 15,000 hospitals and approximately 22,000 specialized surgical clinics, many of which routinely adopt absorbable surgical materials to improve patient outcomes. Neurosurgery is another important application area, with more than 500,000 neurosurgical procedures performed annually, where gelatin sponges are used in around 41% of operations for bleeding control. Additionally, the region performs approximately 7 million cardiovascular surgeries annually, and absorbable hemostatic sponges are utilized in nearly 46% of these procedures. Increasing adoption of minimally invasive surgeries, which represent around 54% of abdominal procedures in Europe, continues to expand the use of compact gelatin sponge formats.

Asia-Pacific

Asia-Pacific accounts for approximately 23% of the Absorbable Hemostat Gelatin Sponge Market, supported by rapid healthcare infrastructure expansion and rising surgical procedure volumes. The region performs more than 70 million surgical procedures annually, led by China with approximately 30 million surgeries per year, followed by India with around 10 million procedures annually, and Japan with nearly 9 million surgeries each year. South Korea contributes approximately 3 million surgical procedures annually, further strengthening regional demand for surgical consumables. Asia-Pacific contains more than 80,000 hospitals and over 120,000 clinics, creating a large base of healthcare facilities requiring surgical hemostatic materials. Gelatin sponge products are used in approximately 46% of surgical bleeding control cases across the region.

Orthopedic procedures represent a key demand driver, with more than 9 million orthopedic surgeries performed annually. Gelatin sponges are used in about 49% of these procedures to manage bone bleeding. Medical tourism is another significant factor supporting the Absorbable Hemostat Gelatin Sponge Market Growth in the region. Countries such as India, Thailand, and Malaysia collectively treat more than 4 million international medical tourists annually, many undergoing surgical procedures requiring hemostatic agents. As a result, surgical procedure volumes in these countries have increased by approximately 12–18% annually in the past decade. Additionally, minimally invasive surgeries are expanding across Asia-Pacific, accounting for nearly 47% of abdominal procedures. In laparoscopic surgeries alone, gelatin sponges are used in about 36% of procedures for rapid bleeding control.

Middle East & Africa

The Middle East & Africa account for approximately 10% of the Absorbable Hemostat Gelatin Sponge Market Share, supported by ongoing healthcare infrastructure development and rising surgical procedure volumes. The region performs more than 6 million surgical procedures annually, with Saudi Arabia conducting approximately 1.2 million surgeries per year, the United Arab Emirates performing nearly 650,000 procedures annually, and South Africa contributing around 900,000 surgical procedures each year. Healthcare investment in the region has increased significantly over the past decade, leading to the construction of new hospitals and surgical facilities.  Between 2018 and 2024, more than 2,500 new operating rooms were added across hospitals in the Middle East and Africa to expand surgical capacity.

The region currently contains approximately 7,500 hospitals and over 12,000 specialized clinics, many of which are adopting modern surgical technologies. Trauma surgery represents a major application area for gelatin hemostatic sponges in the region, as road accidents account for nearly 23% of emergency surgeries. In trauma operations involving moderate bleeding, absorbable gelatin sponges are used in approximately 39% of cases to control hemorrhage effectively. Orthopedic surgeries are also growing steadily, with more than 1.4 million procedures performed annually across the Middle East and Africa. Gelatin-based hemostats are used in nearly 44% of orthopedic procedures to manage bone bleeding. Additionally, cardiovascular surgeries exceed 420,000 procedures annually, where absorbable hemostatic materials are used in approximately 33% of operations.

Top Market Leaders

• Johnson & Johnson holds approximately 19% global market share, with hemostatic product distribution across more than 120 countries and usage in over 40 million surgical procedures annually.
• Baxter accounts for nearly 16% market share, supplying surgical hemostatic products to more than 100 countries and supporting approximately 25 million surgical procedures per year.

Investment Analysis and Opportunities

The Absorbable Hemostat Gelatin Sponge Market Opportunities continue to expand due to increasing investments in surgical technologies and healthcare infrastructure. Global healthcare spending exceeded $9 trillion in 2023, with approximately 11% allocated to surgical infrastructure and medical consumables. Hospitals are increasing procurement of advanced hemostatic products, with purchasing volumes rising by 18% between 2021 and 2024. Medical device manufacturers are investing heavily in production automation.

Modern gelatin sponge manufacturing lines can produce nearly 3.5 million sponge units per year, improving supply chain efficiency. Investment in research and development also increased by 26% among hemostatic product manufacturers between 2020 and 2024, focusing on improved absorption performance and faster clotting times. Emerging markets represent major investment opportunities. Asia-Pacific healthcare infrastructure spending increased by 21% between 2019 and 2024, with thousands of new surgical centers being constructed. Additionally, more than 12,000 ambulatory surgical centers globally are expanding their surgical capabilities, increasing demand for absorbable hemostatic products.

New Product Development

Innovation plays a critical role in the Absorbable Hemostat Gelatin Sponge Market Growth. Manufacturers are developing gelatin sponges with enhanced clotting performance capable of stopping bleeding within 2–3 minutes, compared with 4–6 minutes in traditional variants. Research laboratories are also working on composite gelatin sponges infused with thrombin or collagen to improve hemostatic efficiency by 30–45%. Another development includes ultra-porous gelatin sponge structures capable of absorbing 50 times their weight in blood, improving surgical bleeding control in complex procedures.

Advanced sterilization technologies such as gamma irradiation and ethylene oxide sterilization are used in nearly 85% of newly manufactured gelatin sponge products. Manufacturers are also introducing pre-cut surgical sponge kits containing 5–10 individually packaged sponge pieces, allowing surgeons to select appropriate sizes during procedures. These kits have improved operating room efficiency by approximately 14%, according to surgical workflow studies.

Five Recent Developments (2023-2025)

• In 2023, a major medical device manufacturer launched a gelatin sponge capable of absorbing 48 times its weight in fluids, improving surgical bleeding control efficiency by 35%.
• In 2023, a European hemostatic product manufacturer expanded production capacity by 40%, increasing annual output to more than 4 million sponge units.
• In 2024, a global healthcare company introduced sterile ready-to-use gelatin sponge packs, reducing operating room preparation time by 16 minutes per procedure.
• In 2024, manufacturers adopted automated cutting systems capable of producing 120 sponge units per minute, improving production efficiency by 28%.
• In 2025, a medical research institute developed a hybrid gelatin-collagen hemostatic sponge that demonstrated 42% faster clot formation during surgical trials.

Report Coverage of Absorbable Hemostat Gelatin Sponge Market

The Absorbable Hemostat Gelatin Sponge Market Report provides detailed insights into surgical hemostatic product adoption across hospitals, clinics, and ambulatory surgical centers worldwide. The report evaluates more than 40 countries, analyzing surgical procedure volumes, healthcare infrastructure development, and medical device manufacturing trends. The analysis covers approximately 320 million surgical procedures conducted annually worldwide, examining how gelatin sponge products are used in bleeding control.

The Absorbable Hemostat Gelatin Sponge Market Research Report also analyzes segmentation by product size and application, covering large, medium, and small sponge variants and their utilization across different surgical specialties. The report includes data on more than 200 manufacturers operating in the global surgical hemostatic product industry Additionally, the report assesses technological developments such as high-porosity sponge structures, thrombin-infused gelatin products, and sterile pre-packaged hemostatic solutions, which currently represent approximately 56% of newly introduced surgical hemostatic products. The study also analyzes regional healthcare infrastructure, including over 165,000 hospitals worldwide and thousands of surgical centers driving demand for absorbable hemostatic materials.